Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress

Neoplasia (United States)

Volumn 16, Issue 10, 2014, Pages 824-834

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTANOL; ANILINE DERIVATIVE; CHROMONE DERIVATIVE; HYDROXYBUTYRIC ACID; IMIDAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; MORPHOLINE DERIVATIVE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE; SOMATOMEDIN C RECEPTOR; TERIFLUNOMIDE;

ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FEEDBACK SYSTEM; GENE SILENCING; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANILINE COMPOUNDS; BUTADIENES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; FEEDBACK, PHYSIOLOGICAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXYBUTYRATES; IMIDAZOLES; ISOXAZOLES; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PYRAZINES; RECEPTOR, IGF TYPE 1; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA;

EID: 84988000643     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.08.006     Document Type: Article

References (40)

1. Zhang S, Yu D PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010, 16:4325-4330.
2. Wander SA, Hennessy BT, Slingerland JM Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011, 121:1231-1241.
3. Emerling BM, Akcakanat A Targeting PI3K/mTOR signaling in cancer. Cancer Res 2011, 71:7351-7359.
4. Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, Chong AS In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997, 159:167-174.
5. Xu X, Shen J, Mall JW, Myers JA, Huang W, Blinder L, Saclarides TJ, Williams JW, Chong AS In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 1999, 58:1405-1413.
6. Xu X, Williams JW, Gong H, Finnegan A, Chong AS Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996, 52:527-534.
7. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995, 270:12398-12403.
8. Ruckemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998, 273:21682-21691.
9. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Finnegan A, Chong AS The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997, 159:22-27.
10. Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998, 160:1581-1588.
11. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996, 61:635-642.
12. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau JM, Hambleton P, Spinella-Jaegle S, et al. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc 1996, 28:3088-3091.
13. Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautes C, Westwood R, Kuo EA, Williamson RA, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998, 336(Pt 2):299-303.
14. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011, 471:518-522.
15. Fenton TR and Gout IT. Functions and regulation of the 70 kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43, 47-59.
16. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10:8421-8425.
17. Perez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjold B, Fornander T, Skoog L, and Stal O. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat 128, 713-723.
18. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004, 10:1013-1023.
19. Ben-Sahra I, Howell JJ, Asara JM, and Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323-1328.
20. Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-1323.
21. Dibble CC, Asara JM, Manning BD Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009, 29:5657-5670.
22. Rosner M, Schipany K, and Hengstschlager M. p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6. Amino Acids 42, 2251-2256.
23. Tremblay F, BrÛlé S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2007, 104:14056-14061.
24. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
25. Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009, 8:366-375.
26. Liacini A, Seamone ME, Muruve DA, and Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 90, 1450-1457.
27. Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J Immunol 2007, 179:6479-6484.
28. Copps KD, White MF Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 2012, 55:2565-2582.
29. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
30. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
31. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008, 111:379-382.
32. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J, Hwang C, Alessi DR Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 2010, 431:245-255.
33. Bae EJ, Yang YM, Kim SG Abrogation of hyperosmotic impairment of insulin signaling by a novel class of 1,2-dithiole-3-thiones through the inhibition of S6K1 activation. Mol Pharmacol 2008, 73:1502-1512.
34. Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, and Chen H. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther 9, 429-437.
35. Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient. Nephrol Dial Transplant 2011, 26:3412-3415.
36. Hail N, Jr., Chen P, and Bushman LR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia 12, 464-475.
37. Huang M, Wang Y, Collins M, Mitchell BS, Graves LM A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. Mol Pharmacol 2002, 62:463-472.
38. O'Donnell EF, Kopparapu PR, Koch DC, Jang HS, Phillips JL, Tanguay RL, Kerkvliet NI, and Kolluri SK. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One 7, e40926.
39. Chan V, Charles BG, Tett SE Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 2005, 60:257-264.
40. Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, Ma L, Blinder L, Xiao F, Xu X, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999, 68:100-109.